Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain

BMC Cancer

Gonzalo López-Abente¹  Sergio Mispireta²  Marina Pollán¹ 

[1] Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain

[2] Preventive Medicine Service, La Paz University Hospital, P° de la Castellana 261, 28046 Madrid, Spain

关键词: Spain;    Age-period-cohort;    Epidemiology;    Prostate cancer;    Breast cancer;   

Others  :  1118005
DOI  :  10.1186/1471-2407-14-874

 received in 2014-08-18, accepted in 2014-11-12,  发布年份 2014

【 摘 要 】

Background

Breast cancer in women and prostate cancer are the first and second leading tumour respectively in terms of incidence world-wide. Our objective is to ascertain the similarities and differences between mortality trends in breast cancer among women and prostate cancer in Spain using age-period-cohort models, and analyse the correlation between incidence of breast and prostate cancer at cancer registries locally and world-wide.

Methods

We analysed the independent effects of age, period of death and birth cohort on mortality rates for breast cancer in women and prostate cancer in Spain across the period 1952–2011. Segmented regression analyses were performed to detect and estimate changes in period and cohort curvatures. Correlation among age-adjusted incidence rates at 246 population cancer registries world-wide was analysed for the period 2003–2007.

Results

The mortality trend displayed common characteristics in terms of the annual number of deaths due to these tumours, their adjusted mortality rates and the change points detected in the cohort and period effects. The trend in incidence was very different to that in mortality, due to early detection and progressive improvement in survival. Correlation between the incidence rates of both tumours recorded by registries around the world proved to be a generalised phenomenon.

Conclusions

This study shows that breast cancer mortality in women and prostate cancer mortality and their trends in Spain display visible similarities in terms of the number of deaths due to these tumours, their adjusted mortality rates and the changes experienced by mortality over time. The effects of advances in the diagnosis of both tumours correspond to a decline in mortality which becomes evident after a lag of approximately eight years. Correlation between breast and prostate cancer incidence rates is very high in Spain and at registries on all continents.

【 授权许可】

   
2014 López-Abente et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010.
• [2]Mandal R, St-Hilaire S, Kie JG, Derryberry D: Spatial trends of breast and prostate cancers in the United States between 2000 and 2005. Int J Health Geogr 2009, 8:53. BioMed Central Full Text
• [3]Mistry M, Parkin DM, Ahmad AS, Sasieni P: Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer 2011, 105:1795-1803.
• [4]López-Otín C, Diamandis EP: Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev 1998, 19:365-396.
• [5]Cuzick J: Hormone replacement therapy and the risk of breast cancer. Eur J Cancer 2008, 44:2344-2349.
• [6]Prins GS: Endocrine disruptors and prostate cancer risk. Endocr Relat Cancer 2008, 15:649-656.
• [7]Prentice RL, Sheppard L: Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1990, 1:81-97. discussion 99–109
• [8]Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, Breast and Ovarian Cancer Susceptibility Collaboration, et al.: Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013, 45:353-361. 361e1–2
• [9]Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, et al.: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013, 45:385-391. 391e1–2
• [10]Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, Pastor-Barriuso R, Prostate Cancer Working Group: Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 2010, 21(Suppl 3):iii83-iii89.
• [11]Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, Sánchez-Pérez M-J, Chirlaque M-D, Larrañaga N, Martínez-Cobo R, Tobalina M-C, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martín M-D, Jiménez R, Torrella-Ramos A, Perucha J, Pérez-de-Rada M-E, González S, Rabanaque M-J, Borràs J, Navarro C, Hernández E, Izquierdo A, López-Abente G, Martínez C: Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst 2009, 101:1584-1591.
• [12]Holford TR: Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 1991, 12:425-457.
• [13]Dean C: Testing for overdispersion in Poisson and binomial regression models. J Am Stat Assoc 1992, 87:451-457.
• [14]Muggeo VMR: Estimating regression models with unknown break-points. Stat Med 2003, 22:3055-3071.
• [15]R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005.
• [16]Forman D, Bray F, Brewster D, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher M, Swaminathan R, Ferlay J: Cancer Incidence in Five Continents Vol. X, Volume 164. Lyon: IARC Scientific Publications; 2013.
• [17]Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, Network of Spanish Cancer Screening Programmes (Red de Programas Espanoles de Cribado de Cancer): Cancer screening in Spain. Ann Oncol 2010, 21(Suppl 3):iii43-iii51.
• [18]Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M: Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res BCR 2010, 12:R58. BioMed Central Full Text
• [19]Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E, EUROSCREEN Working Group: Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012, 19(Suppl 1):42-56.
• [20]Páez A, Luján M, Llanes L, Romero I, de la Cal MA, Miravalles E, Berenguer A: PSA-use in a Spanish industrial area. Eur Urol 2002, 41:162-166.
• [21]Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E: [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)]. Arch Esp Urol 2005, 58:403-411.
• [22]De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R: EUROCARE-5 Working Group: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 2014, 15:23-34.
• [23]Kalager M, Adami H-O, Bretthauer M: Too much mammography. BMJ 2014, 348:g1403.
• [24]Autier P, Boniol M, Gavin A, Vatten LJ: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011, 343:d4411.
• [25]Martín M, Pollán M, Jara C, López-Tarruella S, Carrasco E: Proyecto EL Álamo III. Encuesta de evolución de pacientes con cáncer de mama en hospitales del grupo GEICAM 1998–2001. Madrid: GEICAM; 2014.
• [26]Chen Y-C, Page JH, Chen R, Giovannucci E: Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 2008, 68:1582-1591.
• [27]Sakoda LC, Jorgenson E, Witte JS: Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet 2013, 45:345-348.
• [28]Pharoah PDP, Tsai Y-Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Australian Cancer Study, Australian Ovarian Cancer Study Group, et al.: GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013, 45:362-370.
• [29]Pike MC, Pearce CL, Wu AH: Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004, 23:6379-6391.
• [30]World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington DC: AICR; 2007.
• [31]Hsing AW, Sakoda LC, Chua S Jr: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007, 86:s843-s857.
• [32]Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE: Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomark Prev 2005, 14:275-279.
• [33]World Cancer Research Fund / American Institute for Cancer Research: Colorectal Cancer 2011 Report. Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. Washington DC: AICR; 2011.
• [34]Alexander DD, Morimoto LM, Mink PJ, Cushing CA: A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev 2010, 23:349-365.
• [35]Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing H, Martín M: Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study. Br J Cancer 2014, 111:1454-1462.
• [36]Key TJ, Chen J, Wang DY, Pike MC, Boreham J: Sex hormones in women in rural China and in Britain. Br J Cancer 1990, 62:631-636.